



## PRESS RELEASE

### **to-BBB closes EUR 2.5 million financing round to broaden clinical brain tumor study**

Leiden, the Netherlands, 25 April 2013

**to-BBB, the Dutch brain drug delivery company, is proud to announce a EUR 2.5 million financing round supported by its existing investors. The additional resources allow the company to broaden the phase I/IIa study in metastatic and primary brain cancer from two to four indications.**

to-BBB develops therapies for devastating brain diseases by combining its G-Technology<sup>®</sup> with existing drugs to provide a patent-protected formulation with a sustained release profile and enhanced brain delivery. The company's lead product, 2B3-101 for brain cancer, is safely achieving high dose levels and is demonstrating preliminary efficacy in the ongoing phase I/IIa study. While this clinical trial was initially planned to only study brain metastases of breast cancer and glioma, the company will now expand the study to patients with brain metastases of small cell lung cancer and brain metastases of melanoma. With no registered treatments for brain metastases of solid tumors available, 2B3-101 is targeting a high medical need.

to-BBB's second product, 2B3-201 for neuroinflammation, has shown strong preclinical data in diseases like MS, pain and ALS and could be in phase I towards the end of the year. The EUR 2.5 million additional financing by existing shareholders provides a strong basis for further value generation with both products and allows for ample time to establish partnerships for further development.

“At to-BBB we are pleased to have a very supportive group of investors, which allowed us to realize an oversubscribed financing round on top of the available funding from the 2011 Series-B round” says Willem van Weperen, CEO of to-BBB. “This enthusiasm coincides with the first promising data being generated with 2B3-101 in patients with brain metastasis of solid tumors and in primary brain tumors.”

Patrick Krol, Chairman of the Supervisory Board and Managing Partner at Aescap Venture, adds: “to-BBB's G-Technology has gained a lot of momentum by moving into the clinic, showing safe administration in patients and promising signs of efficacy. The Board and Management of to-BBB are fully committed to further develop their two lead products to a phase when they are typically handed over to big pharma.”

#### **About to-BBB**

to-BBB is a clinical stage biotechnology company focusing on enhanced drug delivery across the blood-brain barrier. The Company is developing novel treatments for devastating brain disorders, such as brain cancer and neuroinflammatory disorders, by combining existing drugs with the G-Technology, to-BBB's proprietary brain delivery platform. This technology combines the widely used drug delivery approach of pegylated liposomes with the endogenous tripeptide glutathione as targeting ligand in a novel and safe way. Together with several top tier pharma and biotech companies, to-BBB is investigating the versatility of the G-Technology for drugs that

are unable to reach the brain at systemically tolerable therapeutic doses. to-BBB is applying the G-Technology to enhance the delivery of doxorubicin to the brain for the treatment of brain cancer as its internal lead product 2B3-101, which is currently being tested in a phase I/IIa trial in patients with primary brain tumors as well as patients with brain metastases.

to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).

#### **Contact**

*Willem van Weperen, MSc, MBA*  
Chief Executive Officer

Phone: +31 71 33 222 51

E-mail: [WillemVanWeperen@toBBB.com](mailto:WillemVanWeperen@toBBB.com)

#### **to-BBB technologies BV**

J.H. Oortweg 19  
2333 CH Leiden  
The Netherlands  
[www.toBBB.com](http://www.toBBB.com)

*Sijme Zeilemaker, MSc*  
Business Development Associate

Phone: +31 71 33 222 56

E-mail: [SijmeZeilemaker@toBBB.com](mailto:SijmeZeilemaker@toBBB.com)

#### **to-BBB technologies BV**

J.H. Oortweg 19  
2333 CH Leiden  
The Netherlands  
[www.toBBB.com](http://www.toBBB.com)